Sanctuary Advisors LLC Acquires New Holdings in Fresenius Medical Care AG (NYSE:FMS)

Sanctuary Advisors LLC acquired a new stake in shares of Fresenius Medical Care AG (NYSE:FMS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 39,434 shares of the company’s stock, valued at approximately $983,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP lifted its position in Fresenius Medical Care by 53.1% during the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after purchasing an additional 581 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Fresenius Medical Care during the third quarter valued at approximately $38,000. Venturi Wealth Management LLC lifted its position in Fresenius Medical Care by 1,045.8% during the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after purchasing an additional 4,800 shares during the period. GAMMA Investing LLC lifted its position in Fresenius Medical Care by 43.3% during the fourth quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock valued at $162,000 after purchasing an additional 2,166 shares during the period. Finally, Franklin Street Advisors Inc. NC bought a new position in Fresenius Medical Care during the fourth quarter valued at approximately $201,000. Institutional investors own 8.37% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on FMS shares. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Berenberg Bank began coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price on the stock. Truist Financial boosted their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th. Finally, Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $23.56 on Thursday. The stock has a 50-day simple moving average of $23.40 and a two-hundred day simple moving average of $21.79. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $25.25. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The firm has a market capitalization of $13.83 billion, a PE ratio of 19.47, a P/E/G ratio of 0.76 and a beta of 0.93.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.